Evaluation of QoL based on EORTC C-30 and GINET-21 questionaries in patients with advanced progressive NET during after combine PRRT and CAPTEM therapy

#3260

Introduction: Quality of life is an important end point in clinical trials, yet there are few quality of life questionnaires for neuroendocrine tumors.

Aim(s): The aim of the study was to assess the subjective quality of life (QoL), which did not depend on the stage of cancer treatment, the type of therapy or a significant deterioration of the patient's health in the advanced stage of the disease. A prospective, one-armed, open-label study in patients with histologically proven NET. Overall, 21 patients with pancreas (panNET) n = 14 and midgut n = 7 (NCT04194125).

Materials and methods: Standard QLQ-C30 core and GINET-21 used before each treatment session and then as a follow-up visit every 3 months. Repeated measurements of QoL scores using ANOVA and t-test used to evaluate the differences. Overall in the study were 21 patients 40-78 years (mean age was 59.3±11.5 year) were included to analysis. 13 patients (62%) women and 8 (38%) men.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Słoniewski R, Osowiecka K, Kolasińska-Ćwikła A, Słoniewska A, Czepukojć A,

Keywords: neuroendocrine tumor, pancreatic, midgut,